Participation of PI3K and ERK1/2 pathways are required for human brain vascular smooth muscle cell migration

Document Type

Article

Abstract

Human brain vascular smooth muscle cell (HBVSMC) migration contributes to angiogenesis and several pathological processes in the brain. However, the molecular mechanism of angiogenesis, in which smooth muscle cell contributes, remains unclear. Our study investigates the role of vascular endothelial growth factor (VEGF) in the HBVSMC migration and elucidates the chemotactic signaling pathway mediating this action. We used the in vitro 'scratch' wound method to detect the HBVSMC migration. VEGF(165) (1-40ng/ml) induced the HBVSMC migration in a dose-dependent manner (P<0.05). VEGF(165) does not induce HBVSMC proliferation. Wortmannin, a specific phosphatidylinositol 3-kinase (PI3K) inhibitor, significantly inhibited serine/threonine kinase Akt/protein kinase B (PKB) phosphorylation and reduced HBVSMC migration into the wound edge following VEGF(165) stimulation (P<0.05). PD98059, an extracellular signal-regulated kinase 1/2 (ERK1/2) inhibitor, also significantly inhibited ERK1/2 phosphorylation and reduced the numbers of SMC migration. Parallel distance measurement showed that VEGF(165) induced HBVSMC migration significantly reduced due to inhibition of PI3K or ERK1/2 phosphorylation (P<0.05). Our results demonstrate that VEGF(165) could induce HBVSMC migration but not proliferation in vitro. Inhibiting Akt/PKB or ERK1/2 phosphorylation could reduce VEGF(165) induced HBVSMC migration. We provide the first evidence that activation of PI3K or ERK1/2 pathways are a crucial event in VEGF(165) mediated signal transduction leading to HBVSMC migration.

Medical Subject Headings

Androstadienes (pharmacology); Cerebrovascular Circulation; Chemotaxis (physiology); Enzyme Inhibitors (pharmacology); Flavonoids (pharmacology); Humans; Mitogen-Activated Protein Kinase 1 (antagonists & inhibitors, metabolism); Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases (antagonists & inhibitors, metabolism); Muscle, Smooth, Vascular (cytology, enzymology); Phosphatidylinositol 3-Kinases (metabolism); Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins (antagonists & inhibitors, metabolism); Proto-Oncogene Proteins c-akt; Vascular Endothelial Growth Factor A (antagonists & inhibitors, physiology); Wortmannin

Publication Date

5-1-2004

Publication Title

Neurochemistry international

ISSN

0197-0186

Volume

44

Issue

6

First Page

441

Last Page

6

PubMed ID

14687609

Digital Object Identifier (DOI)

10.1016/j.neuint.2003.07.002

Link to Full Text

Share

COinS